Oppenheimer Holdings, Inc. Reaffirms “Buy” Rating for Vanda Pharmaceuticals Inc. (VNDA)
Oppenheimer Holdings, Inc. reissued their buy rating on shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in a research report report published on Sunday morning. The brokerage currently has a $25.00 target price on the biopharmaceutical company’s stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ Q3 2018 earnings at $0.00 EPS and Q4 2018 earnings at $0.04 EPS.
Other equities research analysts also recently issued research reports about the stock. BidaskClub downgraded shares of Vanda Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, August 11th. Piper Jaffray Companies upped their target price on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an overweight rating in a research note on Thursday, September 14th. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a sell rating to a strong-buy rating and set a $18.00 target price for the company in a research note on Tuesday, August 8th. HC Wainwright set a $18.00 target price on shares of Vanda Pharmaceuticals and gave the company a buy rating in a research note on Thursday, August 3rd. Finally, ValuEngine downgraded shares of Vanda Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, November 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. Vanda Pharmaceuticals has a consensus rating of Buy and a consensus target price of $21.50.
Shares of Vanda Pharmaceuticals (NASDAQ VNDA) opened at $12.85 on Friday. Vanda Pharmaceuticals has a 12 month low of $11.90 and a 12 month high of $18.99.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The firm had revenue of $41.30 million during the quarter, compared to the consensus estimate of $43.90 million. During the same quarter in the prior year, the firm earned ($0.01) earnings per share. The business’s quarterly revenue was up 7.3% on a year-over-year basis. analysts forecast that Vanda Pharmaceuticals will post -0.39 earnings per share for the current fiscal year.
Several hedge funds have recently modified their holdings of the company. Cubist Systematic Strategies LLC increased its position in shares of Vanda Pharmaceuticals by 221.3% during the third quarter. Cubist Systematic Strategies LLC now owns 25,387 shares of the biopharmaceutical company’s stock worth $454,000 after acquiring an additional 17,485 shares in the last quarter. University of Notre Dame DU Lac bought a new stake in shares of Vanda Pharmaceuticals during the third quarter worth $2,824,000. Schwab Charles Investment Management Inc. increased its position in shares of Vanda Pharmaceuticals by 2.5% during the third quarter. Schwab Charles Investment Management Inc. now owns 472,516 shares of the biopharmaceutical company’s stock worth $8,459,000 after acquiring an additional 11,647 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Vanda Pharmaceuticals by 112.2% during the third quarter. Wells Fargo & Company MN now owns 151,693 shares of the biopharmaceutical company’s stock worth $2,715,000 after acquiring an additional 80,209 shares in the last quarter. Finally, Cadence Capital Management LLC bought a new stake in shares of Vanda Pharmaceuticals during the third quarter worth $1,121,000. 87.28% of the stock is owned by institutional investors.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Stock Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.